PTGS2 and glioma: Hence, COX-2 has been proposed as a strong predictor of poor survival and aggressiveness [12, 18] as well as its targeting with specific COX-2 inhibitors is emerging as a potential anti-glioma strategy [12, 14, 23, 24].